基本信息
浏览量:2
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
selected publications
Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir. Journal of medical virology. 2021
Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era. Medical care. 2021
Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City. Drug and alcohol dependence. 2021
Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020
Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. Open forum infectious diseases. 2020
Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing. PloS one. 2020
Funding awarded
Research Training in Infectious Diseases awarded by National Institute of Allergy & Infectious Diseases Co-Investigator 2020 - 2025
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit awarded by National Institute of Allergy & Infectious Diseases Key Personnel 2020 - 2027
ACTG LOC: PF A5379 - Y3 Protocol co-Chair (1560 G YC257) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2027
CoVPN 3004: Phase 3, SARS-CoV-2 Vaccine (Novavax) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2022
CoVPN 3001: Phase 3, SARS-CoV-2 Vaccine (Moderna TX, Inc.) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2022
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636] - PF CRS 7804 awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2021
Specialties and Expertise
Specialties
Public Health-Preventative Medicine
Infectious Disease
Expertise
AIDS (Acquired Immune Deficiency Syndrome)
HIV (Human Immunodeficiency Virus Infection)
Hepatitis C/HIV Coinfection
Dr. Marks is an Associate Professor of Medicine at Weill Cornell Medicine (WCM) where she conducts clinical trials related to HIV, HCV and COVID prevention and treatment. She received Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital (Cornell), where she focused clinical training and research on HIV and hepatitis virus infections and completed Weill Cornell's Master's Degree in Clinical Investigation. She has taken a leadership role advancing the treatment of HIV and hepatitis C in underserved populations at Cornell through clinical, education, and research activities. Her current research focuses on improving treatment outcomes in patients with HIV and hepatitis virus co-infections. Several research projects have focused specifically on people who inject drugs including an ongoing R01-funded study comparing HCV treatment delivery at a community syringe exchange program with usual care. She is the co-chair of an AIDS Clinical Trials Group (ACTG) multi-center study to assesses a novel Hepatitis B vaccine, currently serve on three ACTG protocol teams, and is a member of the ACTG Hepatitis Transformative Science Group. She serves as a co-director of the Cornell HIV/AIDS Clinical Trials Unit, where she conducts several treatment studies related to HIV and hepatitis viruses. She served as co-chair of IDSA/AASLD’s joint guidelines panel for “Recommendations for testing, managing and treating hepatitis C” and as a member of New York State’s HCV guidelines panel. When the COVID pandemic hit New York City, she led the phase 3 studies of remdesivir at Weill Cornell as well as a phase 3 studies of a vaccine for the prevention of COVID.
Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir. Journal of medical virology. 2021
Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era. Medical care. 2021
Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City. Drug and alcohol dependence. 2021
Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020
Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. Open forum infectious diseases. 2020
Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing. PloS one. 2020
Funding awarded
Research Training in Infectious Diseases awarded by National Institute of Allergy & Infectious Diseases Co-Investigator 2020 - 2025
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit awarded by National Institute of Allergy & Infectious Diseases Key Personnel 2020 - 2027
ACTG LOC: PF A5379 - Y3 Protocol co-Chair (1560 G YC257) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2027
CoVPN 3004: Phase 3, SARS-CoV-2 Vaccine (Novavax) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2022
CoVPN 3001: Phase 3, SARS-CoV-2 Vaccine (Moderna TX, Inc.) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2022
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636] - PF CRS 7804 awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2021
Specialties and Expertise
Specialties
Public Health-Preventative Medicine
Infectious Disease
Expertise
AIDS (Acquired Immune Deficiency Syndrome)
HIV (Human Immunodeficiency Virus Infection)
Hepatitis C/HIV Coinfection
Dr. Marks is an Associate Professor of Medicine at Weill Cornell Medicine (WCM) where she conducts clinical trials related to HIV, HCV and COVID prevention and treatment. She received Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital (Cornell), where she focused clinical training and research on HIV and hepatitis virus infections and completed Weill Cornell's Master's Degree in Clinical Investigation. She has taken a leadership role advancing the treatment of HIV and hepatitis C in underserved populations at Cornell through clinical, education, and research activities. Her current research focuses on improving treatment outcomes in patients with HIV and hepatitis virus co-infections. Several research projects have focused specifically on people who inject drugs including an ongoing R01-funded study comparing HCV treatment delivery at a community syringe exchange program with usual care. She is the co-chair of an AIDS Clinical Trials Group (ACTG) multi-center study to assesses a novel Hepatitis B vaccine, currently serve on three ACTG protocol teams, and is a member of the ACTG Hepatitis Transformative Science Group. She serves as a co-director of the Cornell HIV/AIDS Clinical Trials Unit, where she conducts several treatment studies related to HIV and hepatitis viruses. She served as co-chair of IDSA/AASLD’s joint guidelines panel for “Recommendations for testing, managing and treating hepatitis C” and as a member of New York State’s HCV guidelines panel. When the COVID pandemic hit New York City, she led the phase 3 studies of remdesivir at Weill Cornell as well as a phase 3 studies of a vaccine for the prevention of COVID.
研究兴趣
论文共 80 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Annals of internal medicineno. 10 (2023): ITC145-ITC160
Annals of Internal Medicineno. 10 (2023): ITC145-ITC160
引用0浏览0引用
0
0
CLINICAL INFECTIOUS DISEASESno. 3 (2023): 414-418
ANNALS OF INTERNAL MEDICINEno. 10 (2023): ITC146-U31
Kristen Marks,Minhee Kang,Triin Umbleja,Anchalee Avihingsanon,Patcharaphan Sugandhavesa,Andrea L Cox,Hugo Perazzo,Jennifer C Price,Christina Vernon,Stephanie Caruso, Lillian Collins, Shawn Chiambah,
Open Forum Infectious Diseasesno. Supplement_2 (2022)
Open Forum Infectious Diseasesno. 7 (2022)
Drug and Alcohol Dependence Reports (2022): 100109-100109
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn